GORDAGEN GRANTED PATENT FOR DELIVERY TECHNOLOGY

MELBOURNE, Australia, Dec. 17, 2015 /Medianet International-AsiaNet/ --

Gordagen Pharmaceuticals, an Australian company developing evidence-based nutraceuticals and pharmaceuticals, is pleased to announce its Australian patent application* covering its novel delivery technology platform for improving the bioavailability of tocotrienols has been granted. The patent covers Gordagen's novel delivery platforms, including the MELT3(TM) technology being used for its nutraceutical products in the US and Japan and also the delivery technology intended for its prescription portfolio. It also encompasses Gordagen's nutraceutical targets of exercise endurance, delayed onset muscle soreness and heart health, the Company's prescription indications including hyperlipidemia and diabetes, as well as other indications of interest. This provides the company with multiple opportunities for product development and licensing with interested parties. http://mrem.bernama.com/viewsm.php?idm=25944